Keywords: tap, tak-390mr, enters, ph, iii, pharmaceuticals, joint

TAP's TAK-390MR enters Ph III

Article | 05 September 2005

Print This

TAP Pharmaceuticals, a joint venture of Abbott Laboratories and Japan's Takeda has initiated Phase III studies for an investigational new ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in